JP2024506116A5 - - Google Patents
Info
- Publication number
- JP2024506116A5 JP2024506116A5 JP2023531615A JP2023531615A JP2024506116A5 JP 2024506116 A5 JP2024506116 A5 JP 2024506116A5 JP 2023531615 A JP2023531615 A JP 2023531615A JP 2023531615 A JP2023531615 A JP 2023531615A JP 2024506116 A5 JP2024506116 A5 JP 2024506116A5
- Authority
- JP
- Japan
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNPCT/CN2020/132454 | 2020-11-27 | ||
| CN2020132454 | 2020-11-27 | ||
| CNPCT/CN2021/081236 | 2021-03-17 | ||
| CN2021081236 | 2021-03-17 | ||
| PCT/CN2021/133429 WO2022111621A1 (en) | 2020-11-27 | 2021-11-26 | Aminoheteroaryl kinase inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024506116A JP2024506116A (ja) | 2024-02-09 |
| JP2024506116A5 true JP2024506116A5 (https=) | 2024-12-04 |
| JPWO2022111621A5 JPWO2022111621A5 (https=) | 2024-12-04 |
Family
ID=81753779
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023531615A Pending JP2024506116A (ja) | 2020-11-27 | 2021-11-26 | アミノヘテロアリールキナーゼ阻害剤 |
| JP2024531423A Pending JP2024541533A (ja) | 2020-11-27 | 2022-11-23 | アミノヘテロアリールキナーゼ阻害薬 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024531423A Pending JP2024541533A (ja) | 2020-11-27 | 2022-11-23 | アミノヘテロアリールキナーゼ阻害薬 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US20240166635A1 (https=) |
| EP (2) | EP4251613A4 (https=) |
| JP (2) | JP2024506116A (https=) |
| KR (1) | KR20230127228A (https=) |
| CN (2) | CN116528869B (https=) |
| AU (3) | AU2021385745C1 (https=) |
| CA (2) | CA3202990A1 (https=) |
| IL (1) | IL303237A (https=) |
| MX (1) | MX2024006300A (https=) |
| WO (2) | WO2022111621A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20230127228A (ko) * | 2020-11-27 | 2023-08-31 | 올오리온 테라퓨틱스 인크. | 아미노헤테로아릴 키나아제 억제제 |
| CA3207392A1 (en) * | 2021-02-05 | 2022-08-11 | Xiaoxia Yan | Cdk inhibitor |
| EP4532473A1 (en) * | 2022-05-27 | 2025-04-09 | Allorion Therapeutics Inc. | Aminoheteroaryl kinase inhibitors |
| EP4731620A1 (en) * | 2023-06-25 | 2026-04-29 | Allorion Therapeutics Inc | Isotopologues of aminoheteroaryl kinase inhibitors and uses thereof |
| WO2026024674A1 (en) | 2024-07-22 | 2026-01-29 | Genesis Therapeutics, Inc. | Methods of treating skp2-associated cancers |
| EP4725942A1 (en) * | 2024-10-09 | 2026-04-15 | Sibylla Biotech S.p.A. | Compounds active on cyclin d1 pathway and their use |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0004888D0 (en) * | 2000-03-01 | 2000-04-19 | Astrazeneca Uk Ltd | Chemical compounds |
| GB0004890D0 (en) * | 2000-03-01 | 2000-04-19 | Astrazeneca Uk Ltd | Chemical compounds |
| GB0016877D0 (en) * | 2000-07-11 | 2000-08-30 | Astrazeneca Ab | Chemical compounds |
| GB0021726D0 (en) * | 2000-09-05 | 2000-10-18 | Astrazeneca Ab | Chemical compounds |
| EP1343782B1 (en) * | 2000-12-21 | 2009-05-06 | SmithKline Beecham Corporation | Pyrimidineamines as angiogenesis modulators |
| KR100874791B1 (ko) * | 2001-05-29 | 2008-12-18 | 바이엘 쉐링 파마 악티엔게젤샤프트 | Ｃｄｋ-억제 피리미딘, 그의 제조방법 및 약제로서의 용도 |
| GB0113041D0 (en) * | 2001-05-30 | 2001-07-18 | Astrazeneca Ab | Chemical compounds |
| KR20040062557A (ko) * | 2001-11-01 | 2004-07-07 | 얀센 파마슈티카 엔.브이. | 글리코겐 신타제 키나제 3β 억제제로서의아미노벤즈아미드 유도체 |
| GB0205693D0 (en) * | 2002-03-09 | 2002-04-24 | Astrazeneca Ab | Chemical compounds |
| GB0205688D0 (en) * | 2002-03-09 | 2002-04-24 | Astrazeneca Ab | Chemical compounds |
| AU2003212282A1 (en) * | 2002-03-11 | 2003-09-22 | Schering Aktiengesellschaft | Cdk inhibiting 2-heteroaryl pyrimidine, the production thereof, and use thereof as a medicament |
| BR0316680A (pt) * | 2002-11-28 | 2005-10-18 | Schering Ag | Pirimidinas inibidoras de chk, pdk e akt, sua produção e uso como agentes farmacêuticos |
| US7504396B2 (en) * | 2003-06-24 | 2009-03-17 | Amgen Inc. | Substituted heterocyclic compounds and methods of use |
| DE102005008310A1 (de) * | 2005-02-17 | 2006-08-24 | Schering Ag | Verwendung von CDKII Inhibitoren zur Fertilitätskontrolle |
| WO2006122003A2 (en) * | 2005-05-05 | 2006-11-16 | Ardea Biosciences, Inc. | Diaryl-purine, azapurines and -deazapurines as non-nucleoside reverse transcriptase inhibitors for treatment of hiv |
| EP2125781A2 (en) * | 2006-12-20 | 2009-12-02 | Amgen Inc. | Substituted heterocycles and methods of use |
| RU2009140319A (ru) * | 2007-04-02 | 2011-05-10 | Палау Фарма С.А. (Es) | Производные пирролпиримидина |
| NZ580671A (en) * | 2007-04-16 | 2012-03-30 | Hutchison Medipharma Entpr Ltd | Pyrimidine derivatives |
| BRPI0810411B8 (pt) * | 2007-04-18 | 2021-05-25 | Pfizer Prod Inc | derivados de sulfonil amida para o tratamento de crescimento celular anormal, seu sos, bem como composição farmacêutica |
| WO2009022171A1 (en) * | 2007-08-13 | 2009-02-19 | Astrazeneca Ab | Pyridinyiioxy pyridines as alk5 inhibitors |
| EP2179992A1 (de) * | 2008-10-21 | 2010-04-28 | Bayer Schering Pharma Aktiengesellschaft | Sulfonsubstituierte Anlinopyrimidinderivative als CDK-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel |
| AR074209A1 (es) * | 2008-11-24 | 2010-12-29 | Boehringer Ingelheim Int | Derivados de pirimidina utiles para el tratamiento del cancer |
| DE102010014426A1 (de) * | 2010-04-01 | 2011-10-06 | Bayer Schering Pharma Aktiengesellschaft | Verwendung neuer pan-CDK-Inhibitoren zur Behandlung von Tumoren |
| CN103958482B (zh) * | 2011-11-29 | 2017-06-09 | 健泰科生物技术公司 | 作为lrrk2调节剂的氨基嘧啶衍生物 |
| NZ629830A (en) * | 2014-07-14 | 2015-12-24 | Signal Pharm Llc | Methods of treating a cancer using substituted pyrrolopyrimidine compounds, compositions thereof |
| CN110386901B (zh) * | 2018-04-23 | 2022-11-25 | 上海医药工业研究院 | 含磺酰苯胺嘧啶结构的化合物及其作为抗肿瘤药物的应用 |
| US12037323B2 (en) * | 2018-05-03 | 2024-07-16 | Bristol-Myers Squibb Company | Uracil derivatives as Mer-AXL inhibitors |
| WO2020205560A1 (en) * | 2019-03-29 | 2020-10-08 | Incyte Corporation | Sulfonylamide compounds as cdk2 inhibitors |
| JP2023515629A (ja) * | 2020-02-28 | 2023-04-13 | フォチョン・バイオサイエンシーズ・リミテッド | Ｃｄｋ２／４／６阻害剤としての化合物 |
| WO2022096473A1 (en) * | 2020-11-04 | 2022-05-12 | Umicore | A positive electrode active material for rechargeable batteries |
| KR20230127228A (ko) * | 2020-11-27 | 2023-08-31 | 올오리온 테라퓨틱스 인크. | 아미노헤테로아릴 키나아제 억제제 |
| CA3207392A1 (en) * | 2021-02-05 | 2022-08-11 | Xiaoxia Yan | Cdk inhibitor |
-
2021
- 2021-11-26 KR KR1020237021724A patent/KR20230127228A/ko active Pending
- 2021-11-26 EP EP21897121.6A patent/EP4251613A4/en active Pending
- 2021-11-26 CN CN202180079929.6A patent/CN116528869B/zh active Active
- 2021-11-26 AU AU2021385745A patent/AU2021385745C1/en active Active
- 2021-11-26 JP JP2023531615A patent/JP2024506116A/ja active Pending
- 2021-11-26 IL IL303237A patent/IL303237A/en unknown
- 2021-11-26 US US18/254,573 patent/US20240166635A1/en active Pending
- 2021-11-26 CA CA3202990A patent/CA3202990A1/en active Pending
- 2021-11-26 WO PCT/CN2021/133429 patent/WO2022111621A1/en not_active Ceased
-
2022
- 2022-11-23 AU AU2022397678A patent/AU2022397678A1/en active Pending
- 2022-11-23 WO PCT/CN2022/133770 patent/WO2023093769A1/en not_active Ceased
- 2022-11-23 JP JP2024531423A patent/JP2024541533A/ja active Pending
- 2022-11-23 MX MX2024006300A patent/MX2024006300A/es unknown
- 2022-11-23 EP EP22897852.4A patent/EP4436959A4/en active Pending
- 2022-11-23 CN CN202280077473.4A patent/CN118475562A/zh active Pending
- 2022-11-23 CA CA3238970A patent/CA3238970A1/en active Pending
-
2024
- 2024-05-21 US US18/670,469 patent/US20250002480A1/en active Pending
-
2025
- 2025-01-02 AU AU2025200001A patent/AU2025200001A1/en active Pending